Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16680199 | 0.89 | KMT2A (0.59) | KMT2AMEN1THRBMAPTKDM4E | |
| SCHEMBL10570775 | 0.84 | THRB (0.49) | KMT2AMEN1THRBMAPTKDM4E | |
| SCHEMBL10574109 | 0.82 | KMT2A (0.49) | KMT2AMEN1THRBMAPTKDM4E | |
| SCHEMBL15587734 | 0.80 | KMT2A (0.62) | KMT2AMEN1THRBMAPTKDM4E | |
| SCHEMBL15587942 | 0.80 | MEN1 (0.58) | KMT2AMEN1THRBMAPTGAA | |
| SCHEMBL15587727 | 0.80 | KMT2A (0.55) | KMT2AMEN1THRBMAPTKDM4E | |
| SCHEMBL15587899 | 0.80 | KMT2A (0.55) | KMT2AMEN1THRBMAPTKDM4E | |
| SCHEMBL10572660 | 0.80 | NTRK1 (0.50) | KMT2AMEN1THRBMAPTKDM4E | |
| SCHEMBL15587517 | 0.79 | KMT2A (0.48) | KMT2AMEN1THRBMAPTKDM4E | |
| SCHEMBL18814154 | 0.78 | KMT2A (0.78) | KMT2AMEN1THRBMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850237-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | KMT2A 1060/4885MEN1 3296/4885THRB 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.